Amgen Balance Sheet Health
Financial Health criteria checks 1/6
Amgen has a total shareholder equity of $7.5B and total debt of $60.4B, which brings its debt-to-equity ratio to 802.4%. Its total assets and total liabilities are $90.9B and $83.4B respectively. Amgen's EBIT is $6.7B making its interest coverage ratio 2.1. It has cash and short-term investments of $9.0B.
Key information
802.4%
Debt to equity ratio
US$60.40b
Debt
| Interest coverage ratio | 2.1x |
| Cash | US$9.01b |
| Equity | US$7.53b |
| Total liabilities | US$83.36b |
| Total assets | US$90.88b |
Recent financial health updates
Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26
Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Recent updates
Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Financial Position Analysis
Short Term Liabilities: AMGN's short term assets ($26.8B) exceed its short term liabilities ($20.3B).
Long Term Liabilities: AMGN's short term assets ($26.8B) do not cover its long term liabilities ($63.0B).
Debt to Equity History and Analysis
Debt Level: AMGN's net debt to equity ratio (682.7%) is considered high.
Reducing Debt: AMGN's debt to equity ratio has increased from 272.6% to 802.4% over the past 5 years.
Debt Coverage: AMGN's debt is not well covered by operating cash flow (12%).
Interest Coverage: AMGN's interest payments on its debt are not well covered by EBIT (2.1x coverage).